Simonati A, Pezzini F, Moro F, Santorelli F M
Department of Neurological and Movement Sciences-Neurology and Neuropathology, Policlinico GB Rossi, P.le LA Scuro, 37134 Verona, Italy.
Curr Mol Med. 2014 Oct 13;14(8):1043-1051. doi: 10.2174/1566524014666141010154913.
Neuronal Ceroid Lipofuscinoses (NCL) are genetically heterogeneous heritable neurodegenerative disorders with worldwide distribution. They are considered as childhood diseases; however rare adult onset forms are known. NCL have a progressive course, affecting visual, motor and cognitive functions, and are associated with myoclonic epilepsy; behavioural problems can be observed at the onset. The outcome is invariably fatal, mostly during the second or third decade. The denomination is based on pathological criteria, i.e. the presence of intralysosomal storage of autofluorescent lipopigment of glycoprotein origin with characteristic ultrastructural features. The NCL are autosomal recessive diseases (but a rare autosomal dominant form of adult onset). Thirteen NCL associated genes have been identified so far, which allow a definite diagnosis to be reached and provide genetic counselling to the families. Still unidentified NCL genes are foreseen. Allelic heterogeneity is observed in some mutated genes; likewise phenotypic heterogeneity is seen in several NCL. The gene products are either soluble proteins (such as lysosomal enzymes) or membrane proteins related to lysosomes, endoplasmic reticulum, synaptic vesicles. Little is known about pathogenetic mechanisms, leading to storage formation and cell death. Current research is focusing on intracellular trafficking, neurotransmission and storage removal. No cure is available for any form. Innovative treatments led to some results in mouse models related to lysosome hydrolase defects. Evidences that autophagy, oxidative stress, excitotoxicity play roles in NCL cell pathology raise the possibility that selected steps of these processes might become target of treatments, and therefore modify the disease course.
神经元蜡样脂褐质沉积症(NCL)是一类具有遗传异质性的遗传性神经退行性疾病,在全球范围内均有分布。它们被视为儿童疾病;然而,已知存在罕见的成人发病形式。NCL呈进行性病程,影响视觉、运动和认知功能,并与肌阵挛性癫痫相关;在发病时可观察到行为问题。其结局总是致命的,大多在第二个或第三个十年。该命名基于病理学标准,即存在源自糖蛋白的具有特征性超微结构特征的自荧光脂色素在溶酶体内的蓄积。NCL为常染色体隐性疾病(但有一种罕见的成人发病的常染色体显性形式)。到目前为止,已鉴定出13个与NCL相关的基因,这使得能够做出明确诊断并为家庭提供遗传咨询。预计仍有未被鉴定的NCL基因。在一些突变基因中观察到等位基因异质性;同样,在几种NCL中也可见表型异质性。基因产物要么是可溶性蛋白(如溶酶体酶),要么是与溶酶体、内质网、突触小泡相关的膜蛋白。关于导致蓄积形成和细胞死亡的致病机制知之甚少。目前的研究集中在细胞内运输、神经传递和蓄积清除方面。尚无任何形式的治愈方法。创新治疗在与溶酶体水解酶缺陷相关的小鼠模型中取得了一些成果。自噬、氧化应激、兴奋性毒性在NCL细胞病理学中起作用的证据增加了这些过程的某些特定步骤可能成为治疗靶点并因此改变疾病进程的可能性。